Table 4.
Patient characteristics of 94 (2 * 47) matched patients with colorectal carcinoma (match criteria in bold)
| IBD-associated CRC (n = 47) |
Sporadic CRC (n = 47) |
p-value | |
|---|---|---|---|
| n (%) | n (%) | ||
| Age | |||
| Median (range) (years) | 46 (22–80) | 51 (21–79) | 0.166 |
| Sex | |||
| Male | 30 (64) | 30 (64) | 1.0 |
| Female | 17 (36) | 17 (36) | |
| ECOG* | |||
| ECOG 0–1 | 40 (91) | 38 (86) | 0.739 |
| ECOG 2–4 | 4 (9) | 6 (14) | |
| ASA** | |||
| ASA 1–2 | 35 (88) | 39 (91 | 0.732 |
| ASA 3–4 | 5 (12) | 4 (9) | |
| Tumor site | |||
| Right colon | 18 (38) | 18 (38) | 1.0 |
| Left colon | 10 (21) | 10 (21) | |
| Rectum | 19 (40) | 19 (40) | |
| Emergency surgery | |||
| Yes | 2 (4) | 8 (17) | 0.091 |
| No | 45 (96) | 39 (83) | |
| Surgery | |||
| TME/CME | 23 (49) | 47 (100) | < 0.001 |
| (Procto)colectomy | 24 (51) | 0 (0) | |
| Histological type | |||
| Adenocarcinoma (8140/3) | 41 (87) | 44 (94) | |
| Other histological types*** | 6 (13) | 3 (6) | 0.486 |
| Pathological stage (UICC) | |||
| Stage I | 16 (34) | 16 (34) | 1.0 |
| Stage II | 16 (34) | 16 (34) | |
| Stage III | 12 (26) | 12 (26) | |
| Stage yII | 2 (4) | 2 (4) | |
| Stage yIII | 1 (2) | 1 (2) | |
| Multimodal treatment | |||
| Yes | 16 (34) | 13 (28) | 0.509 |
| NO | 31 (66) | 34 (72) | |
| Neoadjuvant treatment for rectal cancer | 3/19 | 3/19 | 1.0 |
| Adjuvant treatment | 15/47 | 11/47 | 0.356 |
| Adjuvant treatment for rectal carcinoma stages II and III | 4/6 | 5/6 | 1.0 |
| Adjuvant treatment for colon carcinoma stage III | 6/7 | 5/7 | 1.0 |
IBD inflammatory bowel disease, CRC colorectal carcinoma, ASA American Society of Anesthesiologists Classification, TME total mesorectal excision, CME complete mesorectal excision. *ECOG performance status in 8 patients unknown; **ASA missing in 11 patients; ***undifferentiated carcinoma, mucinous adenocarcinoma, signet ring cell carcinoma